Corcept Therapeutics Incorporated (CORT)

Market Cap	4.04B -34.8%
Revenue (ttm)	741.17M +17.9%
Net Income	104.66M -25.2%
EPS	0.87 -30.7%
Shares Out	105.19M
PE Ratio	43.92
Forward PE	79.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,063,706
Open	39.90
Previous Close	40.13
Day's Range	38.10 - 40.75
52-Week Range	32.99 - 117.33
Beta	0.26
Analysts	Buy
Price Target	114.20 (+197.71%)
Earnings Date	Feb 25, 2026

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 500
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Analyst Summary

According to 6 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $114.2, which is an increase of 197.71% from the latest price.

Price Target

$114.2

(197.71% upside)

Analyst Consensus: Buy